智通财经网·2025-09-29 14:15Core Viewpoint - Junshi Biosciences (01877) is investing in Beijing Shali Bio-pharmaceutical Co., Ltd. through its subsidiary, Shanghai Juntao Biopharmaceutical Technology Co., Ltd., by subscribing to shares worth RMB 80 million, acquiring a 5.1105% stake in the company [1][2] Group 1 - Junshi Biosciences' subsidiary plans to subscribe to 1,280,623 shares of Beijing Shali for RMB 80 million, while another shareholder, Shanghai Tanying Investment Partnership, will invest RMB 40 million for 640,311 shares [1] - Beijing Shali specializes in tumor immune cell therapy, focusing on tumor-infiltrating lymphocytes (TIL) and has developed the first TIL drug approved for clinical registration in China, GT101, which is currently in critical Phase II clinical trials [1] - The company has also completed dual IND submissions for its first membrane-bound IL-15 complex TIL product, GT201, which is approved to enter Phase I clinical trials [1] Group 2 - The investment is seen as a strategic move to enhance collaboration within the industry and leverage high-quality resources, aligning with the long-term development strategy of Junshi Biosciences [2] - The transaction is expected to have no significant adverse impact on the company's normal operations or financial performance, benefiting the company and all shareholders [2]